Advances in patient care through increasingly individualized therapy

Standfirst | In 2018, the acute myeloid leukaemia treatment landscape expanded notably, with the findings of several trials leading to the approval of novel targeted therapies. Furthermore, comprehensive sequencing of patient samples revealed the effects of co-occurring mutations and gene- expression patterns on drug sensitivity, providing hope that future treatment options will become increasingly precise and personalized.